5. 進行性核上性麻痺 Progressive supranuclear palsy Clinical trials / Disease details

臨床試験数 : 95 / 薬物数 : 119 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04193527 (ClinicalTrials.gov)	June 18, 2020	2/12/2019	A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients	A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls	Parkinsonian Syndrome;Parkinson Disease(PD);Multiple System Atrophy (MSA);Progressive Supranuclear Palsy (PSP)	Drug: DaTSCAN ™ Ioflupane (123I) Injection	GE Healthcare	PPD	Completed	40 Years	80 Years	All	172	Phase 3	China
2	NCT03058965 (ClinicalTrials.gov)	November 29, 2016	12/1/2017	Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain	Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Probable Alzheimer's Disease or Progressive Supranuclear Palsy Compared With Healthy Volunteers	Alzheimer Disease;Healthy Volunteers;Progressive Supranuclear Palsy	Drug: [18F]MNI-958;Drug: [18F]Florbetapir;Drug: DaTscan	Molecular NeuroImaging	NULL	Completed	50 Years	90 Years	All	12	Early Phase 1	United States